



e-ISSN: 2319-8753 | p-ISSN: 2320-6710

IJRSET

International Journal of Innovative Research in
SCIENCE | ENGINEERING | TECHNOLOGY

INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 10, Issue 5, May 2021

ISSN INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA

Impact Factor: 7.512

9940 572 462

6381 907 438

ijirset@gmail.com

www.ijirset.com

Clinics and Characteristics of the Course of Combined Viral Hepatitis

Madumarova Makhfuza Maksimovna, Bayxanova Nasiba, Yakubova Ra'noxon Maksimovna,

Boboyev Muhammadayubxon Murodxono'g'li, Salomov Shoxabbosbek Nozimjono'g'li

Andijan State Medical Institute Senior Lecturer of the Department of Pathological Physiology, Uzbekistan

Andijan State Medical Institute Assistant of the Department of Infectious Diseases, Uzbekistan

Andijan State Medical Institute Assistant of the Department of Infectious Diseases, Uzbekistan

Andijan State Medical Institute 4 St Year Student of the Faculty of Medicine, Uzbekistan

Andijan State Medical Institute 1 St Year Student of the Faculty of Medicine, Uzbekistan

I. INTRODUCTION

Beginning in the second half of the 20th century, viral hepatitis (HB) has become the most common infections, second only to acute respiratory viral infections and, in certain periods, acute intestinal infections. The tension of the epidemiological situation persists at the beginning of the XXI century. The number of registered cases of viral hepatitis is 50-60 times less than the number of flu and acute respiratory infections, but their average duration is 3-5 times longer and the severity of the course is much more pronounced, not to mention the tendency of some forms of viral hepatitis to a chronic course, the development of cirrhosis and even liver cancer [1, 2, 3, 5].

Uzbekistan, according to WHO, belongs to the territories endemic for viral hepatitis. In the dynamics of the incidence of viral hepatitis for 2000-2019, there have been years of rise and fall in the incidence. During the observed period, relatively high incidence rates of viral hepatitis were observed in 2000, when incidence rates were 882.0 per 100 thousand of the population, a dynamic decrease in the incidence rate was observed in subsequent years, however, in 2005 and 2007 there was an abrupt increase in the incidence of viral hepatitis. At the same time, the incidence of viral hepatitis «B. was characterized by a dynamic decrease, from 155.9 in 2000 to 29.5 in 2001 per 100 thousand of the population. In 2001, the first among the Central Asian states in the Republic of Uzbekistan was introduced into the practice of public health services the immunization of newborns against viral hepatitis «B., as a result of which the incidence of viral hepatitis B, as a whole, decreased in comparison with 2000 in 2009 almost 60 times, accounting for 2.6 against 155.9 per 100 thousand people [4, 5, 6].

There are a number of unresolved issues, in particular, specific diagnostic methods (ELISA) are not everywhere introduced, therefore, mainly diagnoses of hepatitis A and hepatitis B are established on the basis of clinical, biochemical and epidemiological data, without taking into account other etiological forms of hepatitis B, mixed (mixed) hepatitis is not detected.

II. GOAL

Determine the etiological structure of hepatitis B, the level and, in part, the clinic of combined (mixed) forms of hepatitis B in children.

III. RESEARCH MATERIAL AND METHODS

Under observation were 1,400 children with acute viral hepatitis from 0 to 14 years old who were admitted to hepatitis wards during the year. A continuous serological examination was conducted to identify the etiology of hepatitis and the level of mixed forms among them. Known hepatitis virus markers were determined in blood serum in an enzyme-linked immunosorbent assay with test systems of ROSH JSC (Russia-Switzerland) and the NPO Diagnostic Systems (Nizhny Novgorod, Russia).

IV. THE RESULTS OF THE RESEARCH AND THEIR DISCUSSION

A planned serological examination of 400 children admitted to the hepatitis departments during the year revealed the etiological structure of hepatitis B in children. At the same time, the specific gravity of GA was 37.3 %, HS - 8.01 %, HS - 9.5 %, GE - 1.0 % and TTV - 1.6 %, combined forms (HB-mixed) were revealed in 40.0 %. Of these, 10.3 % accounted for a combination of HS with HS, 7.0 % - HA with HS, 5.8 % - HS with HD, 3.5 % - HS with TTV, 3.0 % - HS with GE, 2.0 % - GW with TTV and 1.5 % - GW with GE. In 7.5 % cases, the detection of concomitant infections with the identification of markers of 2, 3 and even 4 types of hepatitis B virus.

In accordance with the objectives of the work, 32 cases verified by the detection of serological markers of both infections (HBsAg, Anti-HBc, IgM, HBEAg, HCVc test systems of the second generation) were monitored to study the clinical picture of mixed B + C infections. Control groups with mono-infections comprised 40 children patients with OV and 56 - with OVHS.

In the epidemiological history of HBV patients, 9.3 % of children had a transfusion of blood and its components, 18.1 % had information about various parenteral manipulations (injections, blood sampling, dental procedures, circumcisions, etc.). Moreover, in 18.2 % of children with hepatitis B there was information about contact with a patient with HB virus infection (acute chronic hepatitis B, HBsAg carriage) in the family. At the same time, in 53.4 % of patients, there is no information on parenteral manipulations and contact with patients with HB. In the group of children with mixed hepatitis B + HS infection, the epidemiological history had similar data with the group of children with hepatitis B (transfusion of blood and its preparations - 78.14 various parenteral manipulations - 12.5 %, family contact - 6.2 %, and not there was information in 3.1 % of children). With regard to the severity and course of the disease, with mixed B/C infection compared with patients with HBV, moderate to severe forms were somewhat more frequent ($P < 0.05$). The difference in severity compared with the group of patients with HCV showed a significant increase ($P < 0.001$) severe forms of the disease. Thus, with a mixed course of HBV and HCV, it was possible to identify a number of features in the clinical course, the severity of the disease, the severity of individual clinical symptoms, which must be taken into account in practical work. Interesting results of a comparative analysis of virological indicators in the dynamics of manifest forms of mixed hepatitis B + C.

During the height of the disease, the onset of HBcAg / anti-HBc seroconversion was established significantly earlier, and hence the cessation of HBV active replication in hepatitis B + C compared with monohepatitis B (61.2 and 46.7 %; $p < 0.05$). A possible reason for this could be the simultaneous presence in the patient's body of hepatitis C virus, which to some extent inhibits the hepatitis B virus. In addition, statistically significant differences in the registration of serum HCV markers were observed. First of all, a rarer indication for hepatitis B + C compared with hepatitis C. anti HCV core IgM (13.2; 37.9 % and 24.2 %; $p < 0.05$), and HCV RNA (15.7 and 24 %; $p < 0.05$) indicating active HCV replication. In turn, they suggested the presence of a depressing effect on the part of HBV. The detection of an average of half of patients with both hepatitis C (51.2 %) and hepatitis B C (56.1 %) antibodies to the 4th non-structural protein indicated the chronic nature of HCV infection, Considering the fact that during the period of hepatitis B + C high, HBV DNA was detected in blood serum in 70 % of patients, while HCV RNA in only 16 % ($p < 0.05$), we can confidently talk about the dominant role of HBV in development clinical manifestation with combined HBV / HCV liver damage. The extremely rare simultaneous indication of the genomes of both viruses indicated the possibility of their mutual suppression. Control studies of serum HBV markers during the convalescence period showed that HBeAg / anti HBe seroconversion occurred in all patients with mixed hepatitis B + C, while in some patients with monohepatitis B HBeAg continued to be detected (3.8 %). Moreover, HBsAg (88.4 and 95.2 %; $p < 0.05$) and HBV DNA (23.9 and 52.4 %; $p < 0.05$) were recorded much more often also in the comparison group. The ego testified that elimination from the patient's body took place at a faster, faster pace with the simultaneous presence of HCV in patients with mixed hepatitis during the convalescence period, which was generally comparable with that of monohepatitis C. In both groups, total antibodies continued to be detected, as well as with a similar HCV RNA frequency (17.4 and 21.2

%; $p < 0.05$). Apparently, this situation was determined by the further persistence of HCV. Thus, a comparative analysis of the results of serological and molecular biological studies suggests that during the infection process of the combined HBV / HCV etiology there was a mutual suppression of the activity of hepatotropic viruses. At the same time, the hepatitis B virus dominated in the beginning, which was the reason for the manifest clinical picture of the disease. Subsequently, HBV was eliminated from the patient's body, more rapidly in the presence of hepatitis C.

The subsequent course of HCV infection itself continued in accordance with its inherent patterns. Among the combined HA + HS, the combination of OVGGA + OVGTV was detected in 39 (18.5 %) OVGGA in the presence of HBsAg carriage in 70 (33.2 %) and in OVGGA in the presence of HBsAg in 102 (48.3 %). An analysis of the severity of the disease revealed that with GA in HBsAg carriers, there was no difference in severity compared with the group of patients with OVHA (PO.G5). as for the combined course of OVGGA with OVGTV and OVGGA with OVGTV. then an increase in medium-heavy (respectively 46.0 and 42.0 % versus 37.2 %) and severe forms (respectively 13.0 and 9.0 % versus 2.7 %) is revealed here.

In rebuild; In the combined period of OVGGA + OVGTV and OVGGA combined with HBsAg carriage, a significant slowdown in recovery was noted with a more frequent formation of a protracted course of the disease (10.0 and 8.0 % versus 4.5 %; $P < 0.001$). With a long-term (2-year-old) dispensary, in no one group of patients did the chronization of the process occur. Of 294 patients undergoing OVGTV, 51 revealed an acute delta virus infection. In 16 of them (5.4), co-infection was noted, in 45 (15.4 %) superinfection in carriers of HBsAg. This separation using modern methods of laboratory verification of the diagnosis allowed us to identify a number of clinical features and differences in IOP in co-infection and superinfection. In the first case, the percentage of severe forms increased (19.0 %). Fulminant hepatitis occurred in 25.0 % of cases, with three deaths (19.0 %). Chronic hepatitis was observed in 12.0 % of patients, versus 9.1 % with HBV. In the second case, fulminant hepatitis occurred in 13.0 % of patients with three fatal outcomes (7.0 %), and the formation of chronic hepatitis occurred in 76.0 % of cases. Regarding the nature of the relationship between HBV and HDV, it is determined not only by the use of HBsAg to form the outer shell of HDV, but also by other, not completely prevalent interactions, so HDV inhibits HBV replication, which leads to a decrease in the expression of HBsAg and HBsAg and inhibition of the activity of DNA polymerase during acute infection. One possible announcement of this fact is data on the stimulation of HDV intracellular synthesis of interferon, which inhibits the replication of HBV. Thus, a deltaviral infection, both with co-infection and superinfection, can cause a glaucous and prolonged course of hepatitis B.

V.CONCLUSIONS

Thus, the use of the highly sensitive IFD method allows us to clearly conduct the etiological diagnosis of hepatitis B in children and, thereby, to determine the true ratio of hepatitis B in children, the presence of combined forms of the disease. This allows us to predict the incidence of various forms of hepatitis B in the region and contributes to rational measures to reduce the incidence of hepatitis B.

LITERATURE

1. Azimov, Sh. T. Changes in cellular and humoral immunity in children with viral hepatitis B and C, Honey/ Sh. T. Azimov // Journal of Uzbekistan.-2005.- No. 2.-P. 20-22.
2. Gromova, N. I. Clinical relevance of HGVY RNA detection in patients with chronic viral hepatitis / N. I. Gromova, I. A. Gordeychuk // Journal of Epidemiology and Infectious Diseases. - 2012.- No. 2.- P. 35-41.
3. Zakirkhajaev, A. X. Viral hepatitis / A. X. Zakirkhajaev, B. Tajiev.- Tashkent, 2009.-P. 26-50.
4. Kudasheva, L. V. Organizational foundations of the fight against viral hepatitis in the Republic of Uzbekistan / L. V. Kudasheva // Journal of Infection, Immunity and Pharmacology. - 2010. - No. 1-2,-P. 124-128.
5. Matkarimov, B. D. Toward the epidemiology of viral hepatitis B in the Republic of Uzbekistan / B. D. Matkarimov, D. A. Turnunova // Journal of Infection, Immunity and Pharmacology.- 2010. - No. 1-2. -C. 136-139.
6. Mukasheva, G.K. Clinical and laboratory characteristics of the course of HCV-infection in children / G. K. Mukasheva // Journal of Epidemiology and Infectious Diseases. - 2012. - No. 2.- P. 46-50.



INNO  **SPACE**
SJIF Scientific Journal Impact Factor

Impact Factor:
7.512

ISSN INTERNATIONAL
STANDARD
SERIAL
NUMBER
INDIA



INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 **9940 572 462**  **6381 907 438**  **ijirset@gmail.com**



www.ijirset.com

Scan to save the contact details